Elevance Health, Inc.(ELV)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Elevance Health, Inc. (ELV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ELV at 59.0/100 on a 32-signal composite quality model, placing it at rank #956 of 2,961 stocks — the top half of the AI-ranked universe. ELV scores in the top quartile across revenue scale (99.3), earnings quality (80.9). Areas of concern include free cash flow (36.0) and profitability (38.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Elevance Health, Inc. reports quarterly revenue of $50.5B, net income of $1.5B, an operating margin of 3.5%. Top institutional holders of ELV by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ELV trades on the NYSE exchange and files with the SEC under CIK 1156039. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Elevance Health, Inc. directly from SEC EDGAR.
AI Quality Score
59.0/100
AI Rank
#956
Revenue
$50.5B
Net Income
$1.5B
Free Cash Flow
$1.6B
Operating Margin
3.5%
ELV key financials by period
Elevance Health, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$199.1B
$5.7B
3.6%
FY 2024
10-K
$177.0B
$6.0B
4.4%
FY 2023
10-K
$171.3B
$6.0B
5.0%
FY 2022
10-K
$156.6B
$5.9B
5.3%
FY 2021
10-K
$138.6B
$6.2B
5.5%
FY 2020
10-K
$121.9B
$4.6B
5.2%
Institutions holding ELV
Institutional investors reporting a position in Elevance Health, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-15 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue of $50.5B flat YoY; net income fell 16.6% to $1.45B on higher medical costs and $935M Medicare risk adjustment accrual.
Biggest Revenue Drivers
Premiums$41.3B+0.0% YoY
Premium rate increases in recognition of medical cost trends, offset by membership attrition
Product revenue$6.3B+3.7% YoY
CarelonRx pharmacy services to unaffiliated customers; higher cost per prescription from pricing and product mix
Biggest Revenue Drivers
Total revenue: $50.5B+1.4% YoY
Premiums$41.3B+0.0% YoY
Premium rate increases in recognition of medical cost trends, offset by membership attrition
Product revenue$6.3B+3.7% YoY
CarelonRx pharmacy services to unaffiliated customers; higher cost per prescription from pricing and product mix
Service fees$2.3B+8.3% YoY
Administrative fees from self-funded groups and government program administration
Largest Expense Items
Benefit expense$37.0B+0.9% YoY
Higher medical costs across most lines of business; elevated Medicaid and Medicare trends offset by Individual ACA improvement
Cost of products sold$5.5B+3.8% YoY
Higher cost per prescription reflecting pricing impacts and product mix, despite lower adjusted prescription volumes
Operating expense$5.5B+11.0% YoY
Targeted workforce and technology investments; regulatory expenses; premium tax assessments; transformation program costs
Margins: Benefit expense ratio deteriorated 80 bps to 89.7% on elevated Medicaid and Medicare medical cost trends. Operating expense ratio widened 100 bps to 11.1% from workforce investments, regulatory matters and transformation program; partially offset by improved Individual ACA performance.
Watch Items from the Filing
$935M accrual for Medicare Advantage risk adjustment data resubmission (resolved July 13, 2026); company estimates contingency liability could range $320M below to $320M above accrued amount.
Medical membership declined 1.5% YoY to 44.9M; Medicaid down 4.3%, Medicare Advantage down 15.9%, FEP down 5.4%, partially offset by Employer Group Fee-Based up 1.7%.
Medicaid and Medicare benefit expense ratios elevated due to higher population acuity and utilization post-redetermination; company implementing program improvements and care management strengthening.
Operating gain fell 27.3% to $1.76B on higher medical costs; Health Benefits operating margin compressed 170 bps to 2.1% despite 2.7% revenue growth.
Two main BCBSA antitrust opt-out cases remain pending (Alaska Air, JetBlue; VHS in California); company believes cases without merit; ultimate outcome cannot be determined.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
